{"analyses":[{"ciLowerLimit":"0.339","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.603","estimateComment":"Stratified analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.452","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.76","upperLimit":"4.11","value":"2.83"},{"groupId":"OG001","lowerLimit":"1.45","upperLimit":"2.69","value":"1.61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"Progression-free survival is defined as time from the date of randomization to the date of first observation of objective progression or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"8 mg/kg ramucirumab administered as an intravenous IV injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.","id":"OG000","title":"Ramucirumab + BSC"},{"description":"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.\n\nParticipants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"All randomized participants. Participants were censored in the Ramucirumab arm = 25 and in the Placebo arm = 9. All randomized participants (including the censored participants) were included in the analyses.","reportingStatus":"POSTED","timeFrame":"From Randomization to Objective Progression or Death from Any Cause (Up to 28 Months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}